Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2007, Vol. 12 ›› Issue (6): 714-717.

Previous Articles     Next Articles

Effect of Xuezhikang on LDL subfractions in hyperlipemia patients

PAN Xiao-dong, WANG Lu-ya, LIU Shu, DU Lan-ping   

  1. Department of Cardiology, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing 100029, China
  • Received:2007-02-26 Revised:2007-05-23 Published:2020-11-09

Abstract: AIM:To investigate the effect of Xuezhikang on blood plasm LDL subfractio in hyperlipemia patients and to assess effects of lipid-lowering therapy of Xuezhikang.METHODS:50 hyperlipemia patients as treatment group, and 20 normal persons as control group took part in the experiments. The patients took 1. 2 g Xuezhikang orally everyday for 6 weeks. The serum TC, TG and H-C of patients and normal control were detected by enzyme methods; LDL subfraction were separated by 2% -16% non-denaturing polyacryamide gel electrophoresis. The LDL subfractions distributions were analyzed by the measurement of the area under the band of the scanned gel. Various indexes were measured before and after lipid-lowering therapy, and were contrasted with those in control group.RESULTS:Compared with that in control group the small dense LDL(sLDL) in treatment group was obviously elevated. After lipid-lowering therapy, the levels of sLDL were obviously decreased (P<0. 05).CONCLUSION:Xuezhikang of lipid-lowering therapy can decrease the distribution levels of sLDL and sLDL-C.

Key words: hyperlipoidemia, Xuezhikang, small and low-density lipoprotein

CLC Number: